

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/062556 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 31/20* (2006.01)

(21) International Application Number:
PCT/IB2022/059774

(22) International Filing Date:
12 October 2022 (12.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/256,283 15 October 2021 (15.10.2021) US
63/293,220 23 December 2021 (23.12.2021) US
63/373,539 25 August 2022 (25.08.2022) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BENNETT, Eric Matthew**; c/o Pfizer Inc.,
610 Main Street, Cambridge, Massachusetts 02139 (US).
DIAZ, Fernando Martin; c/o Pfizer Inc., 401 N. Mid-
dletown Road, Pearl River, New York 10965 (US). **DOR-**
MITZER, Philip Ralph; 73 Old Orchard Road, Sherborn,
Massachusetts 01770 (US). **JANSEN, Kathrin Ute**; 200
E 66th Street, Apt. 11C, New York, New York 10065
(US). **MUNOZ-MORENO, Raquel**; c/o Pfizer Inc., 401
N. Middletown Road, Pearl River, New York 10965 (US).
SOLOZANO QUIJANO, Alicia; c/o Pfizer Inc., 401 N.
Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route
206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack,
New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2023/062556 A1

(54) Title: RNA MOLECULES

(57) Abstract: The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.